{"id":137104,"date":"2024-10-22T09:48:16","date_gmt":"2024-10-22T04:18:16","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=137104"},"modified":"2024-10-22T09:48:20","modified_gmt":"2024-10-22T04:18:20","slug":"pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/","title":{"rendered":"Pharma stock in which Mukul Agrawal consistently increased his stake; Do you hold it ?"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2622447167\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>According to business standards, the Indian pharmaceutical industry is a global powerhouse, projected to reach $130 billion by 2030, growing at over 10% annually. Currently valued at $50 billion, India supplies 20% of the world&#8217;s generic medicines and accounts for 60% of global vaccine production, cementing its role as the &#8220;pharmacy of the world.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1447389359\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>With a market capitalization of Rs 17,833.55 crore, the shares of <strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/NEULANDLAB\" target=\"_blank\" rel=\"noreferrer noopener\">Neuland Laboratories Ltd <\/a><\/strong>were trading at Rs 13,900.00 per share, increasing around 2.06 percent as compared to the previous closing price of Rs 13,619.80 apiece.\u00a0<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Matter for Expansion:-&nbsp;<\/strong><\/h2><p>Ace investor Mukul Agrawal has steadily increased his stake in the company since 2020. In September 2020, he held 2.10 lakh shares, rising to 3 lakh shares in 2021, 3.77 lakh in 2022, and 4 lakh in 2023. As of June 2024, he continues to hold 4 lakh shares, equivalent to a 3.12% stake, valued at an estimated Rs 614 crore.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Financial performance:-&nbsp;<\/strong><\/h2><p>The company&#8217;s total income for Q1 FY25 was \u20b9444.4 crores, marking a 21.7% growth from \u20b9365 crores in Q1 FY24. EBITDA (excluding exceptional items) reached \u20b9128.6 crores with a margin of 28.9%, a 174 bps YoY improvement. Gross margins rose to 66.1%.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-3204521213\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Profit after tax for Q1 FY25 increased to \u20b998.3 crores, up from \u20b962.2 crores in Q1 FY24, benefiting from a \u20b920.6 crores exceptional gain from the sale of surplus investment property. The company generated \u20b950.9 crores in free cash flow, with a net debt position of negative \u20b9110.2 crores.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Business Transition:-&nbsp;<\/strong><\/h2><p>The company is transitioning from a focus on prime APIs to a balanced portfolio of CMS (Contract Manufacturing Services) and GDS (Generic Drug Substances). CMS revenues reached \u20b9235 crores, driven by commercial molecules, with strong performance in specialty APIs like Dorzolamide and Donepezil, alongside key products like Mirtazapine and Escitalopram.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Market outlook:-&nbsp;<\/strong><\/h2><p>The company views FY25 as a year of consolidation with normalized revenues and profits, reflecting its investment phase. Growth momentum is expected to pick up from FY26, driven by new manufacturing facilities and commercial launches. Management remains cautiously optimistic despite inherent business variability.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Capacity Expansion:-&nbsp;<\/strong><\/h2><p>The company expects new production blocks in Unit-3 to be operational by H2 FY26. Currently, capacity utilization in Units 1 and 2 exceeds 90%, and ongoing expansion in Unit 1 is underway<\/p><p>to meet growing demand, supporting the company\u2019s future growth and production needs.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Challenges &amp; Customer Engagement:-&nbsp;<\/strong><\/h2><p>Management recognizes risks such as currency fluctuations, raw material cost volatility, and geopolitical instability, and is actively mitigating supply chain risks by seeking alternatives to China. Increased customer interest, particularly from biotech firms, has expanded the project pipeline, while ongoing engagement has strengthened relationships through the\u00a0additional molecule Projects.\u00a0<\/p><div class=\"trade-content-10\" id=\"trade-1924224371\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Company summary:-&nbsp;<\/strong><\/h2><p>Neuland Laboratories Limited is engaged in the manufacturing and selling of bulk drugs. The The company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and is an end-to-end solution provider for the pharmaceutical industry&#8217;s chemistry needs.&nbsp;<\/p><p><strong>Written by:- Abhishek Singh<\/strong><\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Disclaimer<\/strong><\/h2><div class=\"wp-block-image\"><figure class=\"aligncenter\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-2634641621\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>According to business standards, the Indian pharmaceutical industry is a global powerhouse, projected to reach $130 billion by 2030, growing at over 10% annually. Currently valued at $50 billion, India supplies 20% of the world&#8217;s generic medicines and accounts for 60% of global vaccine production, cementing its role as the &#8220;pharmacy of the world.&nbsp; With [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":98971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[23833,5949,17778,9099,948,936],"class_list":["post-137104","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-mukul-agrawal-stake-increase","tag-mukul-agrawal-stock","tag-neuland-laboratories","tag-neuland-laboratories-latest-news","tag-stock-market","tag-stock-market-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock in which Mukul Agrawal consistently increased his stake; Do you hold it ? - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"According to business standards, the Indian pharmaceutical industry is a global powerhouse, projected to reach $130 billion by 2030, growing at over 10% annually. Currently valued at $50 billion, India supplies 20% of the world&#039;s generic medicines and accounts for 60% of global vaccine production, cementing its role as the &quot;pharmacy of the world.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock in which Mukul Agrawal consistently increased his stake; Do you hold it ?\" \/>\n<meta property=\"og:description\" content=\"According to business standards, the Indian pharmaceutical industry is a global powerhouse, projected to reach $130 billion by 2030, growing at over 10% annually. Currently valued at $50 billion, India supplies 20% of the world&#039;s generic medicines and accounts for 60% of global vaccine production, cementing its role as the &quot;pharmacy of the world.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-22T04:18:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-22T04:18:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/\",\"name\":\"Pharma stock in which Mukul Agrawal consistently increased his stake; Do you hold it ? - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"datePublished\":\"2024-10-22T04:18:16+00:00\",\"dateModified\":\"2024-10-22T04:18:20+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"According to business standards, the Indian pharmaceutical industry is a global powerhouse, projected to reach $130 billion by 2030, growing at over 10% annually. Currently valued at $50 billion, India supplies 20% of the world's generic medicines and accounts for 60% of global vaccine production, cementing its role as the \\\"pharmacy of the world.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock in which Mukul Agrawal consistently increased his stake; Do you hold it ?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock in which Mukul Agrawal consistently increased his stake; Do you hold it ? - Trade Brains Features","description":"According to business standards, the Indian pharmaceutical industry is a global powerhouse, projected to reach $130 billion by 2030, growing at over 10% annually. Currently valued at $50 billion, India supplies 20% of the world's generic medicines and accounts for 60% of global vaccine production, cementing its role as the \"pharmacy of the world.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock in which Mukul Agrawal consistently increased his stake; Do you hold it ?","og_description":"According to business standards, the Indian pharmaceutical industry is a global powerhouse, projected to reach $130 billion by 2030, growing at over 10% annually. Currently valued at $50 billion, India supplies 20% of the world's generic medicines and accounts for 60% of global vaccine production, cementing its role as the \"pharmacy of the world.\u00a0","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2024-10-22T04:18:16+00:00","article_modified_time":"2024-10-22T04:18:20+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/","name":"Pharma stock in which Mukul Agrawal consistently increased his stake; Do you hold it ? - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","datePublished":"2024-10-22T04:18:16+00:00","dateModified":"2024-10-22T04:18:20+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"According to business standards, the Indian pharmaceutical industry is a global powerhouse, projected to reach $130 billion by 2030, growing at over 10% annually. Currently valued at $50 billion, India supplies 20% of the world's generic medicines and accounts for 60% of global vaccine production, cementing its role as the \"pharmacy of the world.\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-in-which-mukul-agrawal-consistently-increased-his-stake-do-you-hold-it\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock in which Mukul Agrawal consistently increased his stake; Do you hold it ?"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/137104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=137104"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/137104\/revisions"}],"predecessor-version":[{"id":137109,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/137104\/revisions\/137109"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/98971"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=137104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=137104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=137104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}